Is OmniAb, Inc. (OABIW) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| DJIM | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| MSCI | 7.1% / 33% | 18.3% / 33% | 1.6% / 33% | 11.77% / 5% | ✗ NOT HALAL |
| S&P | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| FTSE | 7.1% / 33% | 18.3% / 33% | 1.6% / 50% | 11.77% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 98.4% | |
| Operating Margin | -147.3% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -23.4% | |
| Return on Assets (ROA) | -13.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$36M |
| Free Cash Flow | -$37M |
| Total Debt | $20M |
| Debt-to-Equity | 7.6 |
| Current Ratio | 4.0 |
| Total Assets | $301M |
Price & Trading
| Last Close | $0.09 |
| Beta | 0.9 |
About OmniAb, Inc. (OABIW)
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Related Halal Stocks in
Frequently Asked Questions
Is OmniAb, Inc. (OABIW) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), OmniAb, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is OmniAb, Inc.'s debt ratio?
OmniAb, Inc.'s debt ratio is not available under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 7.1%.
What are OmniAb, Inc.'s key financial metrics?
OmniAb, Inc. has a market capitalization of N/A, and revenue of $19M. Return on equity stands at -23.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.